Intravesical combined chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin is not indicated for superficial bladder cancer

Urologia Internationalis

Volumn 67, Issue 4, 2001, Pages 289-292

  Tozawa, Keiichi ^a   Okamura, Takehiko ^a   Sasaki, Shoichi ^a   Kawai, Noriyasu ^a   Ito, Yasunori ^a   Hayashi, Yutaro ^a   Kohri, Kenjiro ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

Bacillus Calmette Gu rin; Bladder cancer; Chemoimmunotherapy

Indexed keywords

BCG VACCINE; EPIRUBICIN; INDOMETACIN; SPASMOLYTIC AGENT;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; BLADDER IRRITATION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER RECURRENCE; CONTROLLED STUDY; CYSTOSCOPY; DRUG EFFECT; DRUG INDICATION; DYSURIA; FEMALE; FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POLYURIA; PRIORITY JOURNAL; SUPERFICIAL CANCER; SYSTEMIC DISEASE; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; TUBERCULOSIS; URGE INCONTINENCE; URINE CYTOLOGY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; DRUG THERAPY, COMBINATION; EPIRUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; URINARY BLADDER NEOPLASMS;

EID: 0035216108     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000051005     Document Type: Article

References (20)

1. Intravescial chemotherapy: Treatment selection, techniques, and results
2. Intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer
3. Intravesical doxorubicin for prophylaxis in the management of recurrent superficial bladder cancer
4. A randomized controlled study of intravesical α-2b interferon in carcinoma in situ of the bladder
5. The use of intravesical thiotepa in the management of non-invasive carcinoma of the bladder
6. Bacillus Calmette-Guerin immunotherapy for bladder cancer
7. Bladder cancer: Management of an increasingly common tumor
8. Statistical methods for studying multiple primary malignant neoplasms
9. Biopsy of apparently normal urothelium in patients with bladder carcinoma
10. Factors influencing the recurrence rate of bladder cancer
11. The effect of mitomycin C on superficial bladder cancer
12. Clinicopathological evaluation of repeated courses of intravesical bacillus Calmette-Guerin instillation for preventing recurrence of initially resistant superficial bladder cancer
13. Experimental intravesical therapy for superficial transitional cell carcinoma in a rat bladder tumor model
14. The effects of intravesical chemoimmunotherapy with epirubicin and bacillus Calmette-Guerin for prophylaxis of recurrence of superficial bladder cancer: A preliminary report
15. Toxic and therapeutic activity of 4′-epi-doxorubicin
16. Intravesical instillations of 4′-epi-doxorubicin (epirubicin) in the prophylactic treatment of superficial bladder cancer: Results of a controlled prospective study
17. Intravascial epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): A randomized prospective study
18. Prophylaxis of superficial bladder cancer with a modified intravesical epirubicin treatment schedule
19. Intravesical chemotherapy with epirubicin: A dose response study
20. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer